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ABSTRACT
Background. The prognostic role of pericolic or perirectal
isolated tumor deposits (ITDs) in node-negative colorectal
cancer (CRC) patients is unclear. Rules to deﬁne ITDs as
regional lymph node metastases changed in subsequent
editions of the TNM staging without substantial evidence.
Aim of this study was to investigate the correlation
between ITDs and disease recurrence in stage II and III
CRC patients.
Materials and Methods. The medical ﬁles of 870 CRC
patients were reviewed. Number, size, shape, and location
pattern of all ITDs in node-negative patients were exam-
ined in relation to involvement of vascular structures and
nerves. The correlation between ITDs and the development
of recurrent disease was investigated.
Results. Disease recurrence was observed in 50.0% of
stage II patients with ITDs (13 of 26), compared with
24.4% of stage II patients without ITDs (66 of 270)
(P\.01). Disease-free survival of ITD-positive stage II
patients was comparable with that of stage III patients.
Also within stage III, more recurrences were observed in
ITD-positive patients compared with ITD-negative patients
(65.1 vs. 39.1%, respectively). No correlation was found
between size of ITDs and disease recurrence. More recur-
rences were seen in patients with irregularly shaped ITDs
compared with patients with 1 or more smooth ITDs
present.
Conclusions. Because of the high risk of disease recur-
rence, all node-negative stage II patients with ITDs,
regardless of size and shape, should be classiﬁed as stage
III, for whom adjuvant chemotherapy should be considered.
With more than 600,000 deaths worldwide per year,
colorectal cancer (CRC) is the third most common form of
cancer and the second leading cause of cancer-related death
in the Western world.
1
Currently, the primary method for assessing prognostic
differences among patients is the tumor-node-metastasis
(TNM) staging system, developed by the American Joint
Committee on Cancer and the International Union Against
Cancer (UICC).
2 Main therapeutic decisions are based on
this classiﬁcation.
Isolated tumor deposits (ITDs) are deﬁned as focal
aggregates of adenocarcinoma located in the pericolic or
perirectal fat discontinuous with the primary tumor and
unassociated with a lymph node. Whether these ITDs
should be considered as lymph node involvement when
staging the disease has been the subject of discussion for
many years, resulting in changes in classiﬁcation of the
disease in subsequent editions of the TNM staging system.
Before TNM5, the 5th edition published in 1997, pericolic
and perirectal isolated tumor deposits were not classiﬁed as
positive lymph nodes, regardless of their size and shape,
but were classiﬁed in the pT-category as pT3.
3 In TNM5,
the 3-mm rule was introduced, which states that any
mesocolic or mesorectal tumor deposit of 3 mm in size or
more should be considered as involved lymph node.
4 In the
absence of other evidence of lymph node involvement, this
rule resulted in the reclassiﬁcation of the disease from stage
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to stage III, for which it is. The 3-mm rule was not intro-
duced on the basis of trial data, but on the basis of
unsubstantiated, unpublished work.
5 In TNM6, the current
edition which was published in 2002, the 3-mm rule was
withdrawn. In this edition, the tumor nodule without evi-
dence of residual lymph node is classiﬁed in the pN
category when the nodule has the ‘‘form and the smooth
contour of a lymph node.’’
6 However, also this contour rule
lacks support from clinical evidence and reproducibility is
poor, because of the absence of appropriate guidelines.
5
In the present study we investigated the prevalence of
ITDsinCRCandtherelevanceofITDsandtheirsize,shape,
and location pattern on clinical outcome in stage II CRC
patients.
PATIENTS AND METHODS
Between 1996 and 2005, a total of 870 patients under-
went surgical resection for colorectal cancer (CRC) at the
Kennemer Gasthuis hospital in Haarlem, the Netherlands.
The following information for each patient was
obtained: date of birth, date of surgery, planned or emer-
gency surgery (because of bowel obstruction and/or
perforation), location of the primary tumor (coecal,
ascending, transverse, descending, sigmoid, rectosigmoid,
rectal), adjuvant therapy (radiation and chemotherapy),
date and site of ﬁrst recurrence, and cause of death (CRC
related or other cause). Recurrent disease was deﬁned as
either a peritoneal recurrence or distant metastasis.
Information on pathological variables was obtained
from the histopathology reports.
Tumor stage was classiﬁed according to TNM4.
3 The
following data were collected: tumor size, tumor and nodal
stage, number of total nodes examined, presence of isolated
tumor deposits, differentiation grade, ulceration, mucinous
differentiation, and angioinvasion.
From stage II patients (n = 325) with reported ITDs, all
available slides were reviewed by an independent pathol-
ogist who was unaware of clinical outcome. Apart from
ITD characteristics, that is, number, size, shape (smooth or
irregular, Fig. 1), presence of vasoinvasive and neuroin-
vasive growth were scored. Patients with a history of
colorectal malignancy and those with irradical (macro-
scopically or microscopically) resections were excluded
from the study. Patients with a follow-up period shorter
than 3 months after surgery (due to death or lost in follow
up) were excluded from the disease recurrence analysis.
Statistical Analysis
Chi-square test was applied to assess differences
between groups. Survival analysis was conducted using the
Kaplan–Meier method and the log-rank test. Multivariate
analysis was performed using stepwise logistic regression.
A P value of B.05 was considered statistically signiﬁcant.
Statistical analysis was performed with SPSS 15.0 for
Windows, SPSS Inc., Chicago, IL.
RESULTS
The 870 patients had a mean age of 70.8 years, 466
males (53.6%) and 404 females (46.4%). Of all patients,
169 (19.4%) were classiﬁed as AJCC stage I, 325 (37.4%)
as stage II, 229 (26.3%) as stage III, and 147 patients
(16.9%) as stage IV (Table 1).
In 667 patients (77%) the tumor was located in the colon
and in 203 patients (23%) in the rectum. Of the latter
group, 136 patients (67%) received perioperative radio-
therapy (105 preoperative and 31 postoperative). Median
follow-up was 47.3 months (range 0.0–150.8 months).
The mean number of lymph nodes retrieved for patho-
logical examination was 7.9 (SD 5.1). Recurrent disease
occurred in 12 patients (7.4%) in stage I, in 79 (26.7%) in
stage II, and in 94 patients (44.3%) in stage III.
In 127 of 870 patients (14.8%), ITDs were observed.
The incidence of patients with ITDs increased with higher
tumor stage. No stage I patients had ITDs, 30 (9.2%) in
FIG. 1 Example of an isolated tumor deposit (ITD) with a smooth
(a) and an irregular (b) contour
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pathological characteristics
of 870 CRC patients
Values in parentheses are
percentages unless stated
otherwise
a Patients who died within
3 months after surgery are
excluded
b Patients with stage IV disease
are not included
Stage I
(n = 169)
Stage II
(n = 325)
Stage III
(n = 229)
Stage IV
(n = 147)
Overall
(n = 870)
Sex
Male 81 (47.9) 169 (52.0) 130 (56.8) 86 (58.5) 466 (53.6)
Female 88 (52.1) 156 (48.0) 99 (43.2) 61 (41.5) 404 (46.4)
Age (years)
Mean (SD) 70.8 (11.5) 71.6 (11.6) 70.6 (11.6) 69.0 11.9) 70.8 (11,7)
Median (range) 72.6 (27.6–89.3) 73.2 (28.5–94.4) 72.5 (34.5–94.0) 70.6 (30.8–90.0) 72.6 (27.6–94.4)
Emergency surgery
Yes 1.0 (0.6) 38 (11.7) 37 (16.2) 31 (21.1) 107 (12.3)
No 168 (99.4) 287 (88.3) 192 (83.8) 116 (78.9) 763 (87.7)
Tumor location
Colon 106 (63.3) 260 (80.0) 177 (77.3) 123 (83.7) 667 (76.7)
Rectum 62 (36.7) 65 (20.0) 52 (22.7) 24 (16.3) 203 (23.3)
Tumor size (mm)
Mean (SD) 35.7 (16.4) 42.6 (20.2) 41.4 (19.5) 45.7 (23.7) 41.4 (20.2)
Median (range) 30.0 (10–100) 40.0 (10–130) 40.0 (10–150) 40.0 (10–180) 40.0 (10–180)
Tumor stage
T1 36 (21.8) – 6 (2.6) 0 (0) 42 (4.8)
T2 133 (78.7) – 25 (10.9) 6 (4.1) 165 (19.0)
T3 – 287 (88.3) 177 (77.3) 92 (62.6) 555 (63.8)
T4 – 38 (11.7) 21 (9.2) 49 (33.3) 108 (12.4)
Nodal stage
N0 169 (100) 325 (100) – 51 (34.7) 546 (62.8)
N1 – – 159 (69.4) 52 (35.4) 210 (24.1)
N2 – – 70 (30.6) 44 (29.9) 114 (13.1)
No. of nodes examined
Mean (SD) 5,7 (3.9) 7.9 (5.2) 9.8 (5.2) 7.2 (4.6) 7.9 (5.1)
Median (range) 5 (0–22) 7 (0–38) 9 (1–28) 6 (0–24) 7.0 (0–38)
Isolated tumor deposits
Yes 0 (0) 30 (9.2) 46 (20.1) 51 (34.7) 127 (14.6)
No 169 (100) 295 (90.8) 183 (79.9) 96 (65.3) 743 (85.4)
Histological grade
Well 22 (13.0) 19 (5.8) 10 (4.4) 1 (0.7) 121 (13.9)
Moderately 138 (81.7) 267 (82.2) 176 (76.9) 116 (78.9) 697 (80.1)
Poorly 9 (5.3) 39 (12.0) 43 (18.8) 30 (20.4) 52 (6.0)
Mucinous differentiation
Yes 25 (14.8) 62 (19.1) 51 (22.3) 26 (17.7) 164 (18.9)
No 144 (85.2) 263 (80.9) 178 (77.7) 121 (82.3) 706 (81.1)
Ulceration
Present 78 (46.2) 243 (74.8) 177 (77.3) 102 (69.4) 600 (69.0)
Absent 91 (53.8) 82 (25.2) 52 (22.7) 45 (30.6) 270 (31.0)
Angioinvasion
Present 3 (1.8) 38 (11.7) 79 (34.5) 68 (46.3) 188 (21.6)
Absent 166 (98.2) 287 (88.3) 150 (65.5) 79 (53.7) 682 (78.4)
Recurrent disease
ab b
Yes 12 (7.4) 79 (26.7) 94 (44.3) – 185 (27.7)
No 149 (92.6) 217 (73.3) 118 (55.7) – 484 (72.3)
Follow-up (months)
Median (range) 66.8 (0.1–150.8) 57.3 (0.0–139.6) 44.8 (0.0–148.6) 11.9 (0.0–99.3) 47.3 (0.0–150.8)
ITDs are Associated with Disease Recurrence in CRC 3205stage II, 46 (20.1%) in stage III, and 51 (34.7%) in stage IV
(P\.01).
In total, ITDs were observed in 45 of 546 node-negative
patients, compared with 82 of 324 node-positive patients
(8.2 vs. 25.3%, P\.01).
Stage II CRC Patients
Clinicopathological characteristics of stage II patients
are described in Table 2. Angioinvasive growth of the
primary tumor was observed more frequently in patients
with ITDs compared with ITD-negative patients (40.0 vs.
8.8%, respectively, P\.01). Of 26 patients with ITDs
included in the recurrent disease analysis, 50.0% developed
a recurrence, compared with 24.4% of 270 patients without
ITDs (P\.01). In a multivariate analysis, the presence of
ITDs was maintained as an independent risk of disease
recurrence when adjusted for other known risk factors,
namely T-stage, differentiation grade, and angioinvasion of
the primary tumor, emergency surgery, and total lymph
nodes examined (mean number used as cut-off) (P = .01,
odds ratio [OR]: 3.1; 95% conﬁdence interval [95%
CI]:1.4–6.9).
7 Disease-free survival curves are displayed in
Fig. 2a. Figure 2b shows that the disease-free survival of
stage II patients with ITDs is comparable to that of stage III
patients. For patients with recurrent disease, no signiﬁcant
difference was seen in the site of recurrence (local or dis-
tant) between ITD-positive patients compared with ITD-
negative patients.
Of the 30 stage II patients with ITDs, 4 died within
3 months after surgery. The characteristics of the remain-
ing 26 patients are described in Table 3. In the group of
patients with recurrent disease, the primary tumor showed
more frequently vascular invasion compared to the patients
without recurrence (61.5 vs. 23.1%, respectively, P\.05)
and was located more frequently in the rectum than in the
colon, although this difference is not statistically signiﬁcant
(46.2 and 15.4% respectively, P = .09). In half of the
patients with ITDs, more than 1 ITD was found in the
resection specimen. The recurrence rate in this group was
comparable to patients with only 1 ITD (53.8 vs. 46.2%,
respectively, P = .70).
A total of 20 patients (76.9%) had at least 1 ITD of
3 mm or larger size and 11 patients (42.3%) had at least 1
ITD with a smooth contour. The presence of larger
(C3.0 mm) ITDs was similar in the recurrence group
compared with the nonrecurrence group. Smooth ITDs
were found more often in patients without recurrence (8 vs.
3 respectively, P\.05).
In total, 52 ITDs were found in 30 patients. A smooth
contour was observed in 34 ITDs (65.4%), whereas in 18
(34.6%) an irregular shape was seen. More than half of the
ITDs were not located adjacent to a nerve or vessel.
Perivascular or intravascular location was observed in 19
ITDs (35.5%), and close proximity to a nerve was seen in
10 ITDs (19.2%).
In 17 of the 26 ITD-positive patients (64.4%) analyzed
for disease recurrence, the ITDs were not adjacent to a
nerve or vessel (Table 4). In 5 of the remaining 9 patients,
ITDs did not show a single location pattern, but both per-
ineural and perivascular or intravascular locations of
ITDs was seen. In patients with disease recurrence, more
perivascular or intravascular ITDs were seen (6 vs. 2
respectively, P = .09).
Stage III Patients
For stage III patients recurrent disease was observed in
94 patients (44.3%,Table 1). Within stage III patients, ITD-
positive patients (n = 43) had a higher recurrence rate than
ITD-negative (n = 169) patients (65.1 vs. 39.1%, P\.01).
Disease-free survival curves are displayed in Fig. 2c.
Considering only stage III colon cancer patients who
were treated with (ﬂuorouracil-based) adjuvant chemo-
therapy (n = 83), 63.2% of ITD-positive patients had
recurrent disease, compared with 43.8% of ITD-negative
patients, but this difference lacks statistical signiﬁcance
(P = .14), possible due to the small number of cases.
DISCUSSION
Dependent on the method of examination and the selec-
tion of cases, a large variation in the incidence of ITDs has
been reported in a review study, ranging from 4.5 to 45% of
cases.
5 The presence of ITDs in the absence of lymph node
metastases were present in only 3–25% (mean 8%) of
patients. In our study, ITDs were observed in 14.6% of 870
stage I–IV CRC patients, with 9.2% in stage II and 6.5%
when adding the stage I patients to the node-negative group.
Different theories have been proposed concerning the
origin of isolated tumor deposits. Already in 1935 Gabriel
et al. described their existence and concluded that they
were the result of vascular tumor dissemination.
8 Recent
studies have demonstrated strong correlations between the
presence of ITDs and vascular invasive growth of the
primary tumor.
9–11 In the present study, however, we found
that only 35.5% of the ITDs showed a perivascular or
intravascular location. However, since histological sections
only provide a 2-dimensional sample of the 3-dimensional
tissue, sampling errors may occur, leading to underesti-
mating the prevalence of ITDs associated with vessels.
Possibly, ITDs could actually be lymph node metasta-
ses, in which the pre-existing lymph node is no longer
recognizable because of destruction of lymph node tissue
by tumor cells. As in the present study, several other
3206 E. J. T. Belt et al.studies have demonstrated that the incidence of ITDs is
higher in patients with lymph node metastases than in
patients without nodal involvement.
11–14 Moreover, ITDs
occur more often in patients with extracapsular growth of
lymph node metastases, compared with patients with
lymph node metastases with an intact capsule.
11
TABLE 2 Clinical and
pathological characteristics of
stage II CRC patients
Values in parentheses are
percentages unless stated
otherwise
a Patients who died within
3 months after surgery are
excluded
Overall
(n = 325)
ITD positive
(n = 30)
ITD negative
(n = 295)
P value
Sex
Male 169 (52.0) 18 (60.0) 151 (51.2) NS
Female 156 (48.0) 12 (40.0) 144 (48.8)
Age (years)
Mean (SD) 71.6 (11.6) 73.8 (12.0) 71.3 (11.6) NS
Median (range) 73.2 (28.5–94.4) 79.1 (45.5–94.4) 73.0 (28.5–94.0)
Tumor location and adjuvant therapy
Colon 260 (80.0) 22 (73.3) 238 (80.7) NS
With postoperative chemotherapy 36 (13.8) 5 (22.7) 29 (12.2) NS
Without postoperative chemotherapy 224 (86.2) 17 (77.3) 209 (87.8)
Rectum 65 (20.0) 8 (26.7) 57 (19.3) NS
With perioperative radiotherapy 50 (23.1) 7 (87.5) 43 (75.4) NS
Without perioperative radiotherapy 15 (76.9) 1 (12.5) 14 (24.6) NS
Emergency surgery
Yes 38 (11.7) 3 (10.0) 35 (11.9) NS
No 287 (88.3) 27 (90.0) 260 (88.1)
Tumor size (mm)
Mean (SD) 42.6 (20.2) 37.0 (17.3) 43.1 (20.5) NS
Median (range) 40.0 (10–130) 30.0 (20–100) 40.0 (10–130)
Tumor stage
T3 287 (88.3) 26 (86.7) 261 (88.5) NS
T4 38 (11.7) 4 (13.3) 34 (11.5) NS
No. of nodes examined
Mean (SD) 7.9 (5.2) 6.7 (4.4) 8.0 (5.3) NS
Median (range) 7.0 (0–38) 5.5 (0–16) 7.0 (0–38)
Histological grade
Well 19 (5.8) 0 19 (6.4) NS
Moderately 267 (82.2) 27 (90.0) 240 (81.4) NS
Poorly 39 (12.0) 3 (10.0) 36 (12.2) NS
Mucinous differentiation
Yes 62 (19.1) 5 (16.7) 57 (19.3) NS
No 263 (80.9) 25 (83.3) 238 (80.7)
Ulceration
Yes 243 (74.8) 24 (80.0) 219 (74.2) NS
No 82 (25.2) 6 (20.0) 76 (25.8)
Angioinvasion
Present 38 (11.7) 12 (40.0) 26 (8.8) \.001
Absent 287 (88.3) 18 (60.0) 269 (91.2)
Recurrent disease
a
No 217 (73.3) 13 (50.0) 204 (75.6) .005
Yes 79 (26.7) 13 (50.0) 66 (24.4)
Local 6 (46.2) 29 (43.9) NS
Distant 7 (53.8) 37 (56.1)
Follow-up (months)
Median (range) 57.3 (0.0–139.6) 58.5 (0.3–129.2) 57.3 (0.0–139.6) NS
ITDs are Associated with Disease Recurrence in CRC 3207Assuming ITDs are located in the course of lymph
vessels, recognizable or not, they may reﬂect ‘‘in-transit
metastases,’’ deﬁned as metastasis in which cancerous cells
spread through a lymph vessel and begin to grow and form
a tumor before it reaches the nearest lymph node, a phe-
nomenon well known for melanoma.
15
Considering the origin of ITDs one should take into
account that isolated tumor deposits that are in close
proximity of the primary tumor could actually be a con-
tinuous tumor extension which by the way of sectioning
appears as a separate aggregate.
In some studies the growth pattern of ITDs was inves-
tigated categorizing the deposits in endovascular,
perivascular, endolymphatic, and perineural growth. In a
large number of patients the growth pattern of the ITDs
was heterogeneous.
14,16 In the present study, we observed
this phenomenon as well. In more than half of patients with
perineural, perivascular, or intravascular locations of ITDs,
different patterns were seen.
For ITD-positive patients staged T1–4,N0–2,M0, we
found no difference in recurrence rate between colon and
rectal cancer, conforming to other studies.
5
In some studies it has been shown that patients with
ITDs have an increased risk of tumor recurrence and worse
disease-free survival curves compared with patients with-
out ITDs.
9,10,13,14,16–18 However, most studies included
lymph node positive patients without performing a multi-
variate regression analysis for the N stage.
Until now, few data are available on the relation
between the presence of ITDs without lymph node
metastases and tumor recurrence and survival. Part of this
can be explained by the fact that the different interpre-
tations of ITDs in node-negative CRC patients in the
subsequent editions of staging systems throughout the past
years resulted in a shift of certain stage II patients to stage
III. This leads to changes in treatment strategies within
the group of node-negative ITD-positive patients, which
makes it difﬁcult to study the role of ITDs on outcome of
these patients. The patients in the present study were all
staged according to the 4th edition of the AJCC TNM-
staging system in which node-negative patients with ITDs
are not upstaged to stage III, regardless of size and shape
of the ITDs.
3 This made the study population very suit-
able for analyzing the role of ITDs in node-negative
patients.
In this study we showed a signiﬁcantly worse disease-
free survival for stage II patients with ITDs having a 50%
recurrence rate, compared with 24.4% for ITD-negative
patients. Disease-free survival of ITD-positive stage II
patients was comparable to stage III patients.
Some authors concluded that increasing numbers of ITD
are associated with a poor prognosis, while others did
Disease free
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c
FIG. 2 Disease-free survival curves. a Stage II patients; ITD negative
vs ITD positive patients. b Stage III patients vs ITD positive stage II
patients. c stage III patients; ITD negative vs ITD positive patients.
Patients who died within 3 months after surgery are excluded
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pathological characteristics of
ITD positive stage II CRC
patients
a
Values in parentheses are
percentages unless stated
otherwise
a Patients who died within
3 months after surgery are
excluded
Overall
(n = 26)
Patients
with disease
recurrence
(n = 13)
Patients without
disease recurrence
(n = 13)
P value
Tumor location and adjuvant therapy
Colon 18 (69.2) 7 (53.8) 11 (84.6)
With postoperative chemotherapy 5 (27.8) 1 (14.3) 4 (36.4) NS
Without postoperative chemotherapy 13 (72.2) 6 (85.7) 7 (63.6)
Rectum 8 (30.8) 6 (46.2) 2 (15.4) .09
With perioperative radiotherapy 6 (75.0) 5 (83.3) 2 (100) NS
Without perioperative radiotherapy 2 (25.0) 1 (16.7) 0
Tumor size (mm)
Mean (SD) 36.0 (17.5) 33.6 (14.3) 38.1 (20.2) NS
Median (range) 30.0 (20–100) 30.0 (20–70) 35.0 (20–100)
Tumor stage
T3 25 (96.2) 13 (100) 12 (92.3) NS
T4 1 (3.8) 0 (0) 1 (7.7)
No. of nodes examined
Mean (SD) 5.7 (4.1) 5.1 (5.0) 6.2 (3.0) NS
Median (range) 4.5 (1–14) 3.0 (1–14) 5.0 (2–11)
Histological grade
Well 0 0 0 NS
Moderately 23 (88.5) 13 (100) 10 (76.9)
Poorly 3 (11.5) 0 3 (23.1)
Angioinvasion
Present 11 (42.3) 8 (61.5) 3 (23.1) .047
Absent 15 (57.7) 5 (38.5) 10 (76.9)
Number of ITDs
1 13 (50.0) 6 (46.2) 7 (53.8) NS
2 11 (42.3) 5 (38.5) 6 (46.2)
C3 2 (7.7) 2 (15.3) 0
Size of ITDs
Only ITDs\3.0 mm 6 (23.1) 2 (15.4) 4 (30.8) NS
C1 ITD C 3.0 mm 20 (76.9) 11 (84.6) 9 (69.2)
Shape of ITDs
Only irregular ITDs 15 (57.7) 10 (76.9) 5 (38.5) .047
C1 smooth ITD 11 (42.3) 3 (23.1) 8 (61.5)
TABLE 4 Location pattern of isolated tumor deposits in stage II patients
a
Location Overall
(n = 26)
Patients with disease
recurrence (n = 13)
Patients without disease
recurrence (n = 13)
P value
All ITDs not adjacent to nerve or vessel 17 (64.4) 7 (53.8) 10 (76.9) NS
Perineural in C1 ITD 1 (3.8) 0 1 (7.7) NS
Perivascular or intravascular in C1 ITD 3 (11.5) 3 (23.1) 0
Perineural in C1 ITD and perivascular or
intravascular in C 1 ITD
5 (19.2) 3 (23.1) 2 (15.4) .09
Values in parentheses are percentages unless stated otherwise
a Patients who died within 3 months after surgery are excluded
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12,16 In this study, we found no correlation between the
number of ITDs and the recurrence rate in stage II patients.
Although little evidence is available on the prognostic
value of ITDs in lymph node negative patients, the pres-
ence of ITDs was ﬁrst incorporated in the TNM American
Joint Committee on Cancer (AJCC) staging manuals in
1997.
4 In this (5th) edition a tumor nodule larger than
3 mm in diameter without histological evidence of a
residual lymph node in the nodule was classiﬁed as
regional lymph node metastasis, a smaller nodule was not.
Because substantial evidence was missing, this 3-mm rule
was abandoned, and in the current (6th) edition of the TNM
classiﬁcation system a contour criterion is applied.
6 In this
edition, tumor nodules without evidence of a residual
lymph node that have the form and smooth contour of a
lymph node are considered equivalent to regional lymph
node metastasis. If a nodule has an irregular contour, it
should be classiﬁed in the T category. However, as Nag-
tegaal and Quirke indicated in their review paper, the
evidence on which this contour rule is based is weak and
reproducibility is poor.
5
In this study we examined both the size and shape of the
ITDs of stage II patients and investigated the correlation
with disease recurrence. Taking 3 mm as cutoff point, we
found no correlation between the presence of at least 1
large ITD in the resection specimen and disease recurrence.
Regarding the contour of the ITDs, more patients with
only irregularly shaped ITDs developed disease recurrence
than patients who had 1 or more smooth ITDs. These
ﬁndings do not give any support to the notion to consider
smooth ITDs to be equivalent to regional lymph node
metastasis, as stated in the current edition of the TNM
staging system.
Limitations of the Study
In the Netherlands, standard treatment of stage III colon
cancer patients is surgery followed by adjuvant chemo-
therapy, but this is not always offered to elderly, nonvital
patients. For stage II colon cancer patients, chemotherapy
is not part of the standard care and only offered to high-
risk, vital patients according to the judgment of the local
oncosurgical staff. Because of the retrospective design of
the study, information on considerations to offer adjuvant
chemotherapy was not always available.
For an accurate analysis of the prognostic role of ITDs
in stage III CRC patients, one should stratify patients
according to adjuvant treatment and lymph node status
(N1, N2), but the different subgroups are too small to show
meaningful results. The same counts for stratiﬁcation for
location of the primary tumor and perioperative
radiotherapy.
In conclusion, in this study, we demonstrate that the
presence of isolated tumor deposits in node-negative CRC
patients is a signiﬁcant risk factor for developing disease
recurrence, regardless of the size, shape, number, and
location pattern of the ITDs. In our opinion, all CRC
patients with pericolic or perirectal ITDs should be clas-
siﬁed as stage III, for whom adjuvant treatment should be
considered in order to reduce disease recurrence.
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